A European population-based registry was designed to provide robust information on the epidemiology and characteristics of CML. All cases of newly diagnosed CML in a sample of almost 93 million adults in 20 European countries were registered. These data allow results of prospective trials to be generalized to most countries. The Evaluating Nilotinib Efficacy and […]
